MRI-DWI detection of residual cholesteatoma: moving toward an optimum follow-up scheme
European Archives of Oto-Rhino-Laryngology · 2025
DOI: 10.1007/s00405-024-08939-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2025. Verfasst von Maura C Eggink und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Amsterdam University Medical Centre, Location University of Amsterdam, Amsterdam, The Nethe…. Hauptthemen laut MEDLINE: Cholesteatoma, Middle Ear, Diffusion Magnetic Resonance Imaging. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To analyse diagnostic accuracy of MRI-DWI in detecting residual disease after cholesteatoma surgery and propose an optimum follow-up (FU) scheme.
Method
A retrospective chart review of patients who had cholesteatoma surgery in a tertiary referral centre. 3.0 T non-echo planar diffusion weighted imaging was performed as part of routine FU or indicated on the basis of clinical suspicion of disease. Imaging outcome was verified per-operatively during a second-look procedure or ossicular chain reconstruction. Diagnostic parameters were calculated and stratified by FU length.
Results
For the FU of 664 cholesteatoma surgeries, 1208 MRI-DWI were obtained and 235 second-look procedures were performed. Most MRI-DWI were obtained within 1.5 yrs of surgery. In this period, significantly less true positive MRI-DWI and significantly more false negative MRI-DWI for residual disease were found compared to other FU periods. Scanning after approximately 3 yrs yielded a significantly higher rate of true positive MRI-DWI, while sensitivity surpassed 80%. Younger patients had a higher risk of developing residual disease. Patients undergoing canal wall up surgery, as well as patients < 12 yrs, were at risk for false negative MRI-DWI. Obliteration reduces the risk of residual disease, while leading to less false negative MRI-DWI.
Conclusion
A novel radiologic FU scheme for detecting residual disease is suggested for stable ears after cholesteatoma surgery: standard MRI-DWI approximately 3 and 5 yrs after primary surgery, as well as MRI-DWI after approximately 9 yrs for patients with specific risk factors (i.e., patients < 12 yrs or patients undergoing canal wall up surgery without obliteration).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Head and Neck Surgery, Amsterdam University Medical Centre, Location University of Amsterdam, Amsterdam, The Netherlands. m.c.eggink@amsterdamumc.nl.
- Department of Otorhinolaryngology, Head and Neck Surgery, Amsterdam University Medical Centre, Location University of Amsterdam, Amsterdam, The Netherlands.
- Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centre, Location University of Amsterdam, Amsterdam, The Netherlands.
- Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Zitieren
APA
Eggink, M. C., de Wolf, M. J. F., Ebbens, F. A., de Win, M. M. L., Dikkers, F. G., & van Spronsen, E. (2025). MRI-DWI detection of residual cholesteatoma: moving toward an optimum follow-up scheme. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-024-08939-9
Vancouver
Eggink MC, de Wolf MJF, Ebbens FA, de Win MML, Dikkers FG, van Spronsen E. MRI-DWI detection of residual cholesteatoma: moving toward an optimum follow-up scheme. European Archives of Oto-Rhino-Laryngology. 2025. doi:10.1007/s00405-024-08939-9
BibTeX
@article{Eggink2025,
author = {Eggink, Maura C and de Wolf, Maarten J F and Ebbens, Fenna A and de Win, Maartje M L and Dikkers, Frederik G and van Spronsen, Erik},
title = {MRI-DWI detection of residual cholesteatoma: moving toward an optimum follow-up scheme},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2025},
doi = {10.1007/s00405-024-08939-9}
}
EUVIMED